Back and forth in time: Directing age in iPSC-derived lineages

Brain Research

Volumn 1656, Issue , 2017, Pages 14-26

  Cornacchia, Daniela ^a   Studer, Lorenz ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Aging; Induced in vitro aging; iPSC disease modeling; Maturation; Neurodegenerative diseases; Rejuvenation

Indexed keywords

CELL AGING; CELL FATE; CELL LINEAGE; CELL MATURATION; CELL REGENERATION; COCULTURE; DEGENERATIVE DISEASE; HUMAN; INDUCED PLURIPOTENT STEM CELL; MENTAL DISEASE; MICROFLUIDICS; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; REVIEW; SOMATIC CELL; AGING; ANIMAL; CELL REPROGRAMMING TECHNIQUE; PHYSIOLOGY;

AGING; ANIMALS; CELL LINEAGE; CELLULAR REPROGRAMMING TECHNIQUES; HUMANS; INDUCED PLURIPOTENT STEM CELLS;

EID: 84949426493     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2015.11.013     Document Type: Review

References (137)

1. Arbab, M., Baars, S., Geijsen, N., Modeling motor neuron disease: the matter of time. Trends Neurosci. 37 (2014), 642–652.
2. Ackermann, M., Liebhaber, S., Klusmann, J.H., Lachmann, N., Lost in translation: pluripotent stem cell-derived hematopoiesis. EMBO Mol. Med. 7 (2015), 1388–1402.
3. Ader, M., Tanaka, E.M., Modeling human development in 3D culture. Curr. Opin. Cell. Biol. 31 (2014), 23–28.
4. Achyuta, A.K., et al. A modular approach to create a neurovascular unit-on-a-chip. Lab. chip 13 (2013), 542–553.
5. An, M.C., et al. Genetic correction of Huntington׳s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11 (2012), 253–263.
6. Adler, A.S., et al. Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes. Dev. 21 (2007), 3244–3257.
7. Blesa, J., Phani, S., Jackson-Lewis, V., Przedborski, S., Classic and new animal models of Parkinson׳s disease. J. Biomed. Biotechnol., 2012, 2012, 845618.
8. Bellin, M., Marchetto, M.C., Gage, F.H., Mummery, C.L., Induced pluripotent stem cells: the new patient?. Nat. Rev. Mol. Cell. Biol. 13 (2012), 713–726.
9. Berger, D.R., Ware, B.R., Davidson, M.D., Allsup, S.R., Khetani, S.R., Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell–cell interactions in vitro. Hepatology 61 (2015), 1370–1381.
10. Barres, B.A., The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60 (2008), 430–440.
11. Byers, B., et al. SNCA triplication Parkinson׳s patient׳s iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress. PLoS One, 6, 2011, e26159.
12. Burns, A., Iliffe, S., Alzheimer׳s disease. BMJ, 338, 2009, b158.
13. Burkhardt, M.F., et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol. Cell. Neurosci. 56 (2013), 355–364.
14. Bilican, B., et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 5803–5808.
15. Bahar, R., et al. Increased cell-to-cell variation in gene expression in ageing mouse heart. Nature 441 (2006), 1011–1014.
16. Brack, A.S., et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 317 (2007), 807–810.
17. Burtner, C.R., Kennedy, B.K., Progeria syndromes and ageing: what is the connection? Nature reviews. Mol. Cell. Biol. 11 (2010), 567–578.
18. Chin, J., Selecting a mouse model of Alzheimer׳s disease. Methods Mol. Biol. 670 (2011), 169–189.
19. Chambers, S.M., et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat. Biotechnol. 30 (2012), 715–720.
20. Chambers, S.M., et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27 (2009), 275–280.
21. Chung, W.S., et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature 504 (2013), 394–400.
22. Clarke, L.E., Barres, B.A., Emerging roles of astrocytes in neural circuit development. Nat. Rev. Neurosci. 14 (2013), 311–321.
23. Choi, S.H., et al. A three-dimensional human neural cell culture model of Alzheimer׳s disease. Nature 515 (2014), 274–278.
24. Cooper, O., et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson׳s disease. Sci. Trans. Med., 4, 2012, 141ra190.
25. Camnasio, S., et al. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington׳s disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol. Dis. 46 (2012), 41–51.
26. Conboy, I.M., et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 433 (2005), 760–764.
27. Chen, H., et al. Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter. Nucleic Acids Res. 42 (2014), 1563–1574.
28. Caiazzo, M., et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 476 (2011), 224–227.
29. Das, M., Rumsey, J.W., Bhargava, N., Stancescu, M., Hickman, J.J., A defined long-term in vitro tissue engineered model of neuromuscular junctions. Biomaterials 31 (2010), 4880–4888.
30. Devine, M.J., et al. Parkinson׳s disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat. Commun., 2, 2011, 440.
31. Dimos, J.T., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321 (2008), 1218–1221.
32. Donnelly, C.J., et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80 (2013), 415–428.
33. Dechat, T., et al. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes. Dev. 22 (2008), 832–853.
34. de Magalhaes, J.P., Curado, J., Church, G.M., Meta-analysis of age-related gene expression profiles identifies common signatures of aging. Bioinformatics 25 (2009), 875–881.
35. Ebert, A.D., et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457 (2009), 277–280.
36. Engle, S.J., Puppala, D., Integrating human pluripotent stem cells into drug development. Cell Stem Cell 12 (2013), 669–677.
37. Eiraku, M., et al. Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. Cell Stem Cell 3 (2008), 519–532.
38. Eiraku, M., et al. Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature 472 (2011), 51–56.
39. Eden, A., Gaudet, F., Waghmare, A., Jaenisch, R., Chromosomal instability and tumors promoted by DNA hypomethylation. Science, 300, 2003, 455.
40. Esteller, M., Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet., 2007, R50–R59 16 Spec No 1.
41. Eriksson, M., et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423 (2003), 293–298.
42. Flatt, T., A new definition of aging?. Front. Genet., 3, 2012, 148.
43. Freije, J.M., Lopez-Otin, C., Reprogramming aging and progeria. Curr. Opin. Cell. Biol. 24 (2012), 757–764.
44. Frobel, J., et al. Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem Cell Rep. 3 (2014), 414–422.
45. Fraga, M.F., Esteller, M., Epigenetics and aging: the targets and the marks. Trends Genet.: TIG 23 (2007), 413–418.
46. Feser, J., Tyler, J., Chromatin structure as a mediator of aging. FEBS Lett. 585 (2011), 2041–2048.
47. Gieseck, R.L. 3rd, et al. Maturation of induced pluripotent stem cell derived hepatocytes by 3D-culture. PLoS. One, 9, 2014, e86372.
48. Guo, X., Gonzalez, M., Stancescu, M., Vandenburgh, H.H., Hickman, J.J., Neuromuscular junction formation between human stem cell-derived motoneurons and human skeletal muscle in a defined system. Biomaterials 32 (2011), 9602–9611.
49. Griep, L.M., et al. BBB on chip: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function. Biomed. Microdevices 15 (2013), 145–150.
50. Gaudet, F., et al. Induction of tumors in mice by genomic hypomethylation. Science 300 (2003), 489–492.
51. Horvath, S., DNA methylation age of human tissues and cell types. Genome Biol., 14, 2013, R115.
52. Hu, B.Y., et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 4335–4340.
53. Henderson, C.E., Role of neurotrophic factors in neuronal development. Curr. Opin. Neurobiol. 6 (1996), 64–70.
54. Haass, C., Selkoe, D.J., Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer׳s amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 8 (2007), 101–112.
55. Heyn, H., et al. Distinct DNA methylomes of newborns and centenarians. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 10522–10527.
56. Harries, L.W., et al. Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing. Aging Cell 10 (2011), 868–878.
57. Israel, M.A., et al. Probing sporadic and familial Alzheimer׳s disease using induced pluripotent stem cells. Nature 482 (2012), 216–220.
58. Imaizumi, Y., et al. Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol. Brain, 5, 2012, 35.
59. Juopperi, T.A., et al. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington׳s disease patient cells. Mol. Brain, 5, 2012, 17.
60. Johnson, A.A., et al. The role of DNA methylation in aging, rejuvenation, and age-related disease. Rejuvenation Res. 15 (2012), 483–494.
61. Kondo, T., et al. Modeling Alzheimer׳s disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell 12 (2013), 487–496.
62. Keller, G.M., In vitro differentiation of embryonic stem cells. Curr. Opin. Cell. Biol. 7 (1995), 862–869.
63. Keller, G., Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes. Dev. 19 (2005), 1129–1155.
64. Kriks, S., et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson׳s disease. Nature 480 (2011), 547–551.
65. Khan, J.M., Lyon, A.R., Harding, S.E., The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening. Br. J. Pharmacol. 169 (2013), 304–317.
66. Kadoshima, T., et al. Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 20284–20289.
67. Kunze, A., Giugliano, M., Valero, A., Renaud, P., Micropatterning neural cell cultures in 3D with a multi-layered scaffold. Biomaterials 32 (2011), 2088–2098.
68. Kirkwood, T.B., Melov, S., On the programmed/non-programmed nature of ageing within the life history. Curr. Biol.: CB 21 (2011), R701–R707.
69. Kenyon, C.J., The genetics of ageing. Nature 464 (2010), 504–512.
70. Lutz, W., Sanderson, W., Scherbov, S., The coming acceleration of global population ageing. Nature 451 (2008), 716–719.
71. Lafaille, F.G., et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 491 (2012), 769–773.
72. Lee, G., et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 461 (2009), 402–406.
73. Lee, G., et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat. Biotechnol. 30 (2012), 1244–1248.
74. Liu, G.H., Ding, Z., Izpisua Belmonte, J.C., iPSC technology to study human aging and aging-related disorders. Curr. Opin. Cell. Biol. 24 (2012), 765–774.
75. Lapasset, L., et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes. Dev. 25 (2011), 2248–2253.
76. Le, R., et al. Enhanced telomere rejuvenation in pluripotent cells reprogrammed via nuclear transfer relative to induced pluripotent stem cells. Cell Stem Cell 14 (2014), 27–39.
77. Lockhart, S.T., Mead, J.N., Pisano, J.M., Slonimsky, J.D., Birren, S.J., Nerve growth factor collaborates with myocyte-derived factors to promote development of presynaptic sites in cultured sympathetic neurons. J. Neurobiol. 42 (2000), 460–476.
78. Lancaster, M.A., et al. Cerebral organoids model human brain development and microcephaly. Nature 501 (2013), 373–379.
79. Lesage, S., Brice, A., Parkinson׳s disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18 (2009), R48–R59.
80. Liu, G.H., et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 491 (2012), 603–607.
81. Lin, M.T., Beal, M.F., Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443 (2006), 787–795.
82. Lopez-Otin, C., Blasco, M.A., Partridge, L., Serrano, M., Kroemer, G., The hallmarks of aging. Cell 153 (2013), 1194–1217.
83. Lee, J.S., et al. Meta-analysis of gene expression in the mouse liver reveals biomarkers associated with inflammation increased early during aging. Mech. Ageing Dev. 133 (2012), 467–478.
84. Loffredo, F.S., et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 153 (2013), 828–839.
85. Mica, Y., Lee, G., Chambers, S.M., Tomishima, M.J., Studer, L., Modeling neural crest induction, melanocyte specification, and disease-related pigmentation defects in hESCs and patient-specific iPSCs. Cell Rep. 3 (2013), 1140–1152.
86. Miller, J.D., et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13 (2013), 691–705.
87. Mahmoudi, S., Brunet, A., Aging and reprogramming: a two-way street. Curr. Opin. Cell. Biol. 24 (2012), 744–756.
88. Marion, R.M., et al. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell 4 (2009), 141–154.
89. Maroof, A.M., et al. Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells. Cell Stem Cell 12 (2013), 559–572.
90. McCracken, K.W., et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature 516 (2014), 400–404.
91. Muratore, C.R., et al. The familial Alzheimer׳s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum. Mol. Genet. 23 (2014), 3523–3536.
92. Mitne-Neto, M., et al. Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. Hum. Mol. Genet. 20 (2011), 3642–3652.
93. Marioni, R.E., et al. DNA methylation age of blood predicts all-cause mortality in later life. Genome Biol., 16, 2015, 25.
94. McGann, J.C., Lioy, D.T., Mandel, G., Astrocytes conspire with neurons during progression of neurological disease. Curr. Opin. Neurobiol. 22 (2012), 850–858.
95. Nishimura, T., et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12 (2013), 114–126.
96. Nicholas, C.R., et al. Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. Cell Stem Cell 12 (2013), 573–586.
97. Nakano, T., et al. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell 10 (2012), 771–785.
98. Nguyen, H.N., et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8 (2011), 267–280.
99. Nissan, X., et al. Unique preservation of neural cells in Hutchinson–Gilford progeria syndrome is due to the expression of the neural-specific miR-9 microRNA. Cell Rep. 2 (2012), 1–9.
100. Osorio, F.G., et al. Nuclear lamina defects cause ATM-dependent NF-kappaB activation and link accelerated aging to a systemic inflammatory response. Genes. Dev. 26 (2012), 2311–2324.
101. Patterson, M., et al. Defining the nature of human pluripotent stem cell progeny. Cell. Res. 22 (2012), 178–193.
102. Pagliuca, F.W., et al. Generation of functional human pancreatic beta cells in vitro. Cell 159 (2014), 428–439.
103. Prigione, A., Fauler, B., Lurz, R., Lehrach, H., Adjaye, J., The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. Stem Cells 28 (2010), 721–733.
104. Pfrieger, F.W., Barres, B.A., Synaptic efficacy enhanced by glial cells in vitro. Science 277 (1997), 1684–1687.
105. Polymeropoulos, M.H., et al. Mapping of a gene for Parkinson׳s disease to chromosome 4q21–q23. Science 274 (1996), 1197–1199.
106. Pfisterer, U., et al. Direct conversion of human fibroblasts to dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 10343–10348.
107. Rezania, A., et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol. 32 (2014), 1121–1133.
108. Reinhardt, P., et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 12 (2013), 354–367.
109. Rando, T.A., Chang, H.Y., Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock. Cell 148 (2012), 46–57.
110. Rivenbark, A.G., et al. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics: Off. J. DNA Methylation Soc. 7 (2012), 350–360.
111. Seibler, P., et al. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J. Neurosci.: Off. J. Soc. Neurosci. 31 (2011), 5970–5976.
112. Suhr, S.T., et al. Telomere dynamics in human cells reprogrammed to pluripotency. PLoS One, 4, 2009, e8124.
113. Suhr, S.T., et al. Mitochondrial rejuvenation after induced pluripotency. PLoS One, 5, 2010, e14095.
114. Shi, Y., Kirwan, P., Smith, J., Robinson, H.P., Livesey, F.J., Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat. Neurosci. 15:S471 (2012), S477–S486.
115. Srikanth, P., Young-Pearse, T.L., Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells. J. Neurogenetics 28 (2014), 5–29.
116. Soldner, F., et al. Parkinson׳s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136 (2009), 964–977.
117. Soldner, F., et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146 (2011), 318–331.
118. Sanchez-Danes, A., et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson׳s disease. EMBO Mol. Med. 4 (2012), 380–395.
119. Su, Y.C., Qi, X., Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Hum. Mol. Genet. 22 (2013), 4545–4561.
120. Sanders, L.H., et al. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson׳s disease patients: reversal by gene correction. Neurobiol. Dis. 62 (2014), 381–386.
121. Sproul, A.A., et al. Characterization and molecular profiling of PSEN1 familial Alzheimer׳s disease iPSC-derived neural progenitors. PLoS One, 9, 2014, e84547.
122. Sareen, D., et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Trans. Med., 5, 2013, 208ra149.
123. Tang, X., et al. Astroglial cells regulate the developmental timeline of human neurons differentiated from induced pluripotent stem cells. Stem Cell Res. 11 (2013), 743–757.
124. Takebe, T., et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 499 (2013), 481–484.
125. Talens, R.P., et al. Epigenetic variation during the adult lifespan: cross-sectional and longitudinal data on monozygotic twin pairs. Aging Cell 11 (2012), 694–703.
126. Unternaehrer, J.J., Daley, G.Q., Induced pluripotent stem cells for modelling human diseases. Philosophical transactions of the Royal Society of London. Ser. B Biol. Sci. 366 (2011), 2274–2285.
127. Ullian, E.M., Sapperstein, S.K., Christopherson, K.S., Barres, B.A., Control of synapse number by glia. Science 291 (2001), 657–661.
128. Vonsattel, J.P., DiFiglia, M., Huntington disease. J. Neuropathol. Exp. Neurol. 57 (1998), 369–384.
129. Villeda, S.A., et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat. Med. 20 (2014), 659–663.
130. Villeda, S.A., et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477 (2011), 90–94.
131. Woodard, C.M., et al. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson׳s disease. Cell. Rep. 9 (2014), 1173–1182.
132. Weidner, C.I., et al. Aging of blood can be tracked by DNA methylation changes at just three CpG sites. Genome Biol., 15, 2014, R24.
133. Yagi, T., et al. Modeling familial Alzheimer׳s disease with induced pluripotent stem cells. Hum. Mol. Genet. 20 (2011), 4530–4539.
134. Yoshida, M., et al. Modeling the early phenotype at the neuromuscular junction of spinal muscular atrophy using patient-derived iPSCs. Stem Cell Rep. 4 (2015), 561–568.
135. Zhang, Y.M., Hartzell, C., Narlow, M., Dudley, S.C. Jr., Stem cell-derived cardiomyocytes demonstrate arrhythmic potential. Circulation 106 (2002), 1294–1299.
136. Zhang, Y., et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78 (2013), 785–798.
137. Zhang, G., et al. Hypothalamic programming of systemic ageing involving IKK-beta, NF-kappaB and GnRH. Nature 497 (2013), 211–216.